Sinemet®

DRUG4 trials

Sponsors

Intec Pharma Ltd., Bial - Portela C S.A., Acorda Therapeutics

Conditions

Parkinson DiseaseParkinson's DiseaseParkinson's Disease (PD)

Phase 1

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa

CompletedNCT02774564

Bial - Portela C S.A.Parkinson's Disease

Start: 2005-09-30End: 2005-11-30Updated: 2016-05-19

A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets

CompletedNCT02812394

Acorda TherapeuticsParkinson Disease

Start: 2016-06-30End: 2016-09-30Updated: 2016-10-26

Phase 2

Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients

CompletedNCT02834507

Bial - Portela C S.A.Parkinson's Disease (PD)

Start: 2005-03-31End: 2005-11-30Updated: 2016-07-15

Phase 3

A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients

Intec Pharma Ltd.Parkinson's Disease

Start: 2016-03-31End: 2019-12-31Target: 420Updated: 2019-08-08